Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. Our lead program uses Heidelberg Pharma’s proprietary ATAC technology embracing innovative antibody design, linker technology and the payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers.
This approach brings the promise of superiority to enfortumab vedotin, a high-profile ADC for urothelial cancer which received US FDA accelerated approval in December 2019. We are also exploring opportunities to develop a broader pipeline of additional best- or first-in-class ADCs driven by therapeutic need.
Emergence is led by a strong management team supported by a network of world-leading experts in immuno-oncology and leading European investors.
Dr. Jack ElandsChief Executive Officer
Dr. Jack Elands is the co-founder and Chief Executive Officer of Emergence Therapeutics and a member of the Executive Board. He is also the founder of Talix Therapeutics and Chief Executive Officer of BliNK Biomedical. Previously, he served as co-founder and Chief Executive Officer of Amakem Therapeutics where, under his leadership, Amakem developed a new class of glaucoma drug and managed the development up until phase 2b trials, after which the program was out-licensed to a Korean group. Dr. Elands was previously Chief Executive Officer of Vitec, Chief Business Officer of Silicos and VP of Business Development at Sidec AB. He started his pharmaceutical career at Marion Merrell Dow (later HMR and Aventis, now Sanofi). Dr. Elands holds a PhD in Neuropharmacology from the Rudolf Magnus Institute at University of Utrecht (Netherlands) and the CNRS INSERM Center for Pharmacology and Endocrinology in Montpellier (France).
Carsten DehningChief Financial Officer
Carsten Dehning is Chief Financial Officer at Emergence Therapeutics and a member of the Executive Board. He has over 20 years’ experience serving as a Chief Executive Officer and Chief Financial Officer at a number of healthcare companies including DeveloGen, Aspireo Pharmaceuticals, Albireo, Biovertis and Bourn Hall International. Previously, Mr Dehning is regularly adising companies in the healthcare sector as well as healthcare investors. Mr Dehning holds a Diploma in business administration from the University of Göttingen, Germany.
Dr. Xavier PrevilleChief Scientific Officer
Dr. Xavier Preville is the co-founder and Chief Scientific Officer of Emergence Therapeutics. He previously served as Chief Scientific Officer at Talix Therapeutics and worked for Transgene, where he was responsible for managing the pre-clinical development of various immuno-therapeutics including viral therapeutic vaccines, oncolytic viruses and monoclonal antibodies. Dr. Preville previously worked for BT Pharma (now Genticel), where he successfully led the pre-clinical development and production team. Dr Preville is a cellular immunologist by trade, with more than 15 years industrial experience. He holds a PhD in cellular biology from the Claude Bernard Lyon I University.
Dr. Florence LhospiceChief Development Officer
Dr. Florence Lhospice is Chief Development Officer of Emergence Therapeutics. She previously served as Senior Director at Innate Pharma, where she led the ADC pre-clinical programs. While at Innate Pharma, Dr. Lhospice was head of chemistry, manufacturing and control processes (CMC) for 5 years, after which she was in charge of the development of an ADC technology for a site specific conjugation. Dr. Lhospice holds a PhD in Pharmacy from the Pharmacy School of University Joseph Fourier in Grenoble and the University of Montreal, a Masters degree from the University Claude Bernard in Lyon and the EM Lyon Business School and obtained a PhD in human pathology-oncology from the Medical School of the University of Aix-Marseille.